OnKure Therapeutics (NASDAQ:OKUR) Price Target Lowered to $27.00 at HC Wainwright

OnKure Therapeutics (NASDAQ:OKUR) had its target price cut by HC Wainwright from $34.00 to $27.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, OnKure Therapeutics currently has an average rating of “Hold” and an average target price of $27.00.

OnKure Therapeutics Trading Up 3.2%

NASDAQ OKUR opened at $3.90 on Monday. The company has a market cap of $52.85 million, a PE ratio of -0.88 and a beta of 0.45. OnKure Therapeutics has a 12 month low of $1.70 and a 12 month high of $5.28. The stock has a 50 day moving average of $2.86 and a 200-day moving average of $2.88.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Monday, March 9th. The company reported ($0.99) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16. As a group, sell-side analysts predict that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in OnKure Therapeutics during the second quarter worth $25,000. Bailard Inc. acquired a new position in shares of OnKure Therapeutics in the second quarter valued at $34,000. Jane Street Group LLC bought a new position in shares of OnKure Therapeutics in the fourth quarter valued at about $56,000. Barclays PLC raised its position in shares of OnKure Therapeutics by 4,286.8% in the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after purchasing an additional 26,621 shares during the period. Finally, Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics during the 2nd quarter worth about $71,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.